Classical neurotransmitters and neuropeptides involved in schizophrenia: How to choose the appropriate antipsychotic drug?

Current Drug Therapy

Volumn 8, Issue 2, 2013, Pages 132-143

  Werner, Felix Martin ^a,b   Coveñas, Rafael ^b  

^a Höhere Berufsfachschule für Altenpflege und Ergotherapie der Euro Sch Pößneck   (Germany)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Acetylcholine; Cholecystokinin; Dopamine; GABA; Glutamate; Neuronal network; Neurotensin; Serotonin

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ARIPIPRAZOLE; CARIPRAZINE; CHOLECYSTOKININ; CLOZAPINE; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; DYNORPHIN; ENKEPHALIN; GALANIN; GASTRIN RELEASING PEPTIDE; GLUTAMIC ACID; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LURASIDONE; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTRANSMITTER; OLANZAPINE; OXYTOCIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN; ZIPRASIDONE;

ARTICLE; BODY WEIGHT DISORDER; BRAIN REGION; COHORT ANALYSIS; DISEASE PREDISPOSITION; DRUG MECHANISM; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GENETIC SUSCEPTIBILITY; HALLUCINATION; HIPPOCAMPUS; HUMAN; HYPOTENSION; INSULIN RESISTANCE; LIMBIC SYSTEM; NERVE CELL NETWORK; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SCHIZOPHRENIA;

EID: 84893002219     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/15748855113089990003     Document Type: Article

References (69)

1. Klosterkötter J. Indicated prevention of schizophrenia. Dtsch Arztebl Int 2008; 105: 532-9.
2. Thomas SP, Nandhra HS, Singh SP. Pharmacological treatment of first-episode schizophrenia: a review of the literature. Prim Care Companion CNS Disord 2012; 14: PCC. 11r01198.
3. Davidson M, Keffe RS, Mohs RC, et al. L-dopa challenge and relapse in schizophrenia. Am J Psychiatry 1987; 144: 934-8.
4. Werner FM. Schizophrenia: from the genetic localization to the cellular mechanism. Klin Neuro 2006; 37: 19-20.
5. Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1A) receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl.) 2011; 218: 579-87.
6. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011; 338: 605-14.
7. Vinson PN, Conn PJ. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 2011; 62: 1461-72.
8. Li Z, Boules M, Williams K, Peris J, Richelson E. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res 2010; 1311: 28-36.
9. Collier DA, Li T. The genetics of schizophrenia: glutamate not dopamine? Eur J Pharmacol 2003; 480: 177-84.
10. Maher RA, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012; 18: S1-20.
11. Nilsson M, Waters S, Waters N, Carlsson A, Carlsson ML. A behavioural pattern analysis of hypoglutaminergic mice-effects of four different antipsychotic agents. J Neural Transm 2001; 108: 1181-96.
12. Andersson RH, Johnston A, Herman PA, Winzer-Serhan UH, Karavanova I, Vullhorst D. Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proc Natl Acad Sci USA 2012; 109: 13118-23.
13. Werner FM, Coveñas R. Neuropeptides involved in schizophrenia. Curr Top Neurochem 2005; 4: 35-49.
14. Picada JN, Dos Santos Bde J, Celso F, et al. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice. Acta Pharmacol Sin 2011; 32: 1235-32.
15. Burstein ES, Carlsson ML, Owens M, et al. II. In vitro evidence that (-)-OSU-6162 and (+)-OSU-6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm 2011; 118: 1523-33.
16. Gupta M, Kaur H, Jajodia A, et al. Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia. Curr Mol Med 2011; 11: 732-43.
17. Aas M, Djurovic S, Athanasiu L, et al. Serotonin transporter gene polymorphism, childhood trauma, and cognition in patients with psychotic disorders. Schizophr Bull 2011; 38: 15-22.
18. Linck VM, Bessa MM, Hermann AP, Iwu MM, Okunji CO, Elisabetsky E. 5-HT(2 A/C) receptors mediate the antipsychoticlike effect of alstonine. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 15-22.
19. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag 2011; 7: 239-50.
20. Liu Y, Tang Y, Pu W, Zhang X, Zhao J. Concentration of DA, Glu and GABA in brain tissues in schizophrenia developmental model rats induced by MK-801. Zhong Nan Da Xue Xue Bao Yi Ban 2011; 36: 712-9.
21. Paine TA, Slipp LE, Carlezon WA Jr. Schizophrenia-like attentional deficits following blockade of prefrontal cortex GABAA receptors. Neuropsychopharmacology 2011; 36: 1703-13.
22. Atack JR. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci 2010; 2: 231-60.
23. Koychev I, Barkus E, Ettinger U, et al. Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drugs treatments in schizophrenia. Psychopharmacology 2011; 25: 1207-25.
24. Modhaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2011; 37: 4-15.
25. Werner, FM. Therapiemöglichkeiten medikamentös bedingter extrapyramidal bedingter Störungen. Neurol. Int. Akt-I 2008; 206.
26. Watt M, Schober DA, Hitchkock S, et al. Pharmacological characterization of LY-593, 093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist. J Pharmacol Exp Ther 2011; 338: 622-32.
27. Dencker D, Wörtwein G, Weikop P, et al. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline. J Neurosci 2011; 31: 5905-8.
28. Wallace TL, Porter RH. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011; 81: 891-903.
29. Dutra SJ, Stoeckel LE, Carlini SV, Pazzagalli DA, Evins AE. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl.) 2012; 219: 25-34.
30. Werner FM, Coveñas R. In: Focus on Neuropeptide Research; Coveñas, Mangas, Nárvaez, Eds. Transworld Research Network: Trivandrum 2007; pp. 299-399.
31. Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 2010; 120: 455-70.
32. Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy: a focus on antiepileptic drugs. Curr Med Chem 2011; 18: 4933-48.
33. O'Connor W. T. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J Neurosci Methods 2001; 109: 31-9.
34. Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 2010; 169: 1652-61.
35. Sanjuan J, Toirac I, González JC, et al. A possible association between the CCK-AR gene and persistent auditory hallucinations in schizophrenia. Eur Psychiatry 2004; 19: 349-53.
36. Nikisch G, Baumann P, Liu T, Mathé, AA. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int J Neuropsychopharmacol 2011; 15: 1051-61.
37. Weatherspoon JK, González-Alvear GM, Frank AR, Werling LL. Regulation of [3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophr Res 1996; 21: 51-62.
38. Perreault ML, Hasbi A, Alijaniaram M, et al. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 2010; 19: 36625-34.
39. Tejeda HA, Chefer VI, Zapata A, Shippenberg TS. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRFinduced prepulse inhibition deficits in the rat. Psychopharmacology (Berl) 2010; 210: 231-40.
40. Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S. Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 1991; 83: 273-7.
41. Meller CA, Henriques JA, Schwartsmann G, Roesler R. The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice. Peptides 2004; 25: 585-8.
42. Karomitsu J, Yokoi A, Kawai T, et al. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Brain Res Gen Expr Patterns 2001; 1: 17-21.
43. Karl T, Chesworth R, Duffy L, Herzog H. Acoustic startle response and sensorimotor gating in a genetic mouse model for the Y1 receptor. Neuropeptides 2010; 44: 233-9.
44. Morris H. M, Stopczynski RE, Lewis DA. NPY mRNA expression in the prefrontal cortex: selective reduction in the superficial white matter of subjects with schizoaffective disorder. Schizophr Res 2000; 115: 261-9.
45. Caceda R, Kinkead B, Nemeroff CB. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? Semin Clin Neuropsychiatry 2003; 8; 94-108.
46. Kitagbi P. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr Opin Drug Discov Devel 2002; 5: 764-76.
47. Oliveros A, Heckman MG, Del Pilar Corena-McLeod M, Williams K, Boules M, Richelson E. Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine and NT69L. J Exp Biol 2010; 213: 4232-9.
48. Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl.) 1999; 141: 93-8.
49. Elman I, Lukas S, Shoaf SE, Rott D, Adler C, Breier A. Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J Psychopharmacol 2003; 17: 317-23.
50. Ring RH, Schechter LE, Leonard SK, et al. Receptor and behavioral pharmacology of WAY-267, 464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010; 58: 69-77.
51. Katayama T, Hattori T, Yamada K, Matsuzaki S, Tohyama M. Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms? Pharmacogenomics 2009; 10: 1967-78.
52. Kopa M, Ishquro H, Horiuchi Y, et al. Replication study of association between ADCYAP1 gene polymorphisms and schizophrenia. Psychiatr Genet 2010; 20: 123-5.
53. Ishihama T, Ago Y, Shintani N, et al. Environmental factors during early developmental period influence psychobehavioral abnormalities in adult PACAP-deficient mice. Behav Brain Res 2010; 209: 274-80.
54. Alamy SS, Jarskog LF, Sheitman BB, Liebermann JA. Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features. Schizophr Res 2004; 66: 183-6.
55. Sakai K, Maeda K, Chihara K, Kaneda H. Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides 1995; 29: 157-61.
56. Semenova S, Hoyer D, Geyer MA, Markou A. Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats. Neuropeptides 2010; 44: 421-9.
57. Matthe AA. Neuropeptides and eletroconvulsive treatment. J ECT 1999; 15: 60-75.
58. Werkman TR, McCreary AC, Kruse CG, Wadman WJ. NK3 receptors mediate an increase in firing rate of midbrain dopamine neurons of the rat and the guinea pig. Synapse 2011; 65: 814-26.
59. Gabriel SM, Davidson M, Haroutunian V, et al. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry 1996; 39: 79-81.
60. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004; 61: 544-55.
61. Talbot K, Thompson EW, Smith RJ, et al. Dysbindin-1 is reduced in intrinsic, glutaminergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004; 133: 1353-63.
62. Fatjó-Vilas M, Papiol S, Estrada G, et al. Dysbindin-1 gene contributes differentially to early-and adult-onset forms of functional psychosis. Am J Med Genet B Neuropsychiatr Genet 2011; 156: 322-33.
63. Wei YL, Li CX, Li SB, Liu Y, Hu L. Association study of monoamino oxidase A/B genes and schizophrenia in Han Chinese. Behav Brain Funct 2011; 7: 42.
64. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23: 6315-26.
65. Pommepuy N, Janueal D. Catatonia: resurgence of a concept. A review of the international literature. Encéphale 2002; 28: 481-92.
66. Guay DR. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. Consult Pharm 2011; 26: 579-82.
67. Weston-Green K, Huang XF, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 2011; 22: 364-73.
68. Tajima K, Fernández H, López-Ibor JJ, Carrasco JL, Díaz-Marsá M. Tratamientos para la esquizofrenia. Revisión crítica sobre la farmacología y mecanismos de acción de los antipsicóticos. Acta Esp Psiquitr 2009; 37: 330-42.
69. Elsworth JD, Groman SM, Jentsch JD, et al. Asenapine effects on cognitive and monamine dysfunction elicited by subchronic phencyclidine administration. Neuropsychopharmacology 2011; 62: 1442-52.